Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
155 hedge funds and large institutions have $805M invested in Esperion Therapeutics in 2021 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 44 increasing their positions, 54 reducing their positions, and 23 closing their positions.
0% more capital invested
Capital invested by funds: $803M → $805M (+$2.04M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 23
1% less funds holding
Funds holding: 157 → 155 (-2)
8.04% less ownership
Funds ownership: 110.77% → 102.73% (-8%)
19% less repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 54
58% less call options, than puts
Call options by funds: $8.35M | Put options by funds: $19.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$19.1M |
| 2 |
Swedbank
Stockholm,
Sweden
|
+$6.4M |
| 3 |
Millennium Management
New York
|
+$5.42M |
| 4 |
Citigroup
New York
|
+$4.54M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$33.9M |
| 2 |
State Street
Boston,
Massachusetts
|
-$11.9M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$10.2M |
| 4 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
-$9.86M |
| 5 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
-$8.06M |
ESPR Hedge Fund Activity: Q1 2021 in Review
155 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q1 2021, worth a combined $805M — up 0.25% from $803M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of ESPR and 21 opened new positions — a net loss of 2 holders — while 54 trimmed existing stakes and 44 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $19.1M. The largest seller was Bellevue Group, cutting an estimated $33.9M.
- 155 institutional investors held Esperion Therapeutics (ESPR) as of Q1 2021, down from 157 in Q4 2020.
- Funds reported $805M of Esperion Therapeutics stock for Q1 2021, up 0.25% quarter-over-quarter.
- 21 funds opened new Esperion Therapeutics positions in Q1 2021 and 23 closed out, a net change of -2 holders.
- The largest Esperion Therapeutics buyer in Q1 2021 was Point72 Asset Management, an estimated $19.1M added.
- The largest Esperion Therapeutics seller in Q1 2021 was Bellevue Group, an estimated $33.9M sold.
Based on aggregated 13F filings for Q1 2021.